{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T18:27:31Z","timestamp":1787682451262,"version":"build-2784847793"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>The aim of this study is to explore the relationship between gene polymorphism and the efficacy and adverse drug reactions (ADRs) of opioid analgesics, improve medication safety, and promote personalized medication.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>First, the method of evidence-based medicine retrieval and evaluation was adopted to systematically summarize the opioid analgesic drug ADR and efficacy-related gene loci currently recommended by guidelines, authoritative genetic information databases, and low-bias clinical trial studies. The gene loci with strong correlation evaluation were selected as target genes for testing. Then, a clinical case\u2013control trial was designed, divided into two groups: the ADR research group and the dose demand research group. A total of 480 enrolled patients were tested for target genes. Finally, the gene test results were evaluated for ADR association and drug dose association using SPSS 26.0 software and the SNPStats tool.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Four genes were selected for detection: <jats:italic>CYP2D6<\/jats:italic>, <jats:italic>CYP3A5*3<\/jats:italic>, <jats:italic>ABCB1<\/jats:italic>, and <jats:italic>OPRM1<\/jats:italic>. The results of the correlation analysis showed that, in the ADR research group, compared with the control subgroup, the AG + GG type distribution of <jats:italic>OPRM1<\/jats:italic> (rs1799971, A&amp;gt;G) was lower, and the AA type distribution was higher in the observation subgroup (<jats:italic>P<\/jats:italic> &amp;lt; 0.05). Individual statistics of patients using oxycodone also revealed differences in <jats:italic>OPRM1<\/jats:italic> (rs1799971, A&amp;gt;G). In particular, in the observation subgroup, the AA type accounted for 56.35% and the AG + GG type accounted for 43.65%; in the control subgroup, the AA type accounted for 38.28% and the AG + GG type accounted for 61.72%; compared with the control subgroup, the proportion of <jats:italic>OPRM1<\/jats:italic> (rs1799971, A&amp;gt;G) AA type was higher in the experimental subgroup (<jats:italic>P<\/jats:italic> &amp;lt; 0.05). The SNPStats program was used to analyze the association between single-nucleotide polymorphism (SNP) and ADR in five genetic models. The results showed that co-dominant, dominant, and allele models all suggested a significant association between <jats:italic>OPRM1<\/jats:italic> (rs1799971) and ADR incidence (<jats:italic>P<\/jats:italic> &amp;lt; 0.05). In the dose demand evaluation group, the results showed that there was no significant difference in genotype distribution between the observation subgroup (high-dose group) and the control subgroup (low-dose group) (<jats:italic>P<\/jats:italic> &amp;gt; 0.05). However, attention should be paid to the <jats:italic>ABCB1<\/jats:italic> gene. At the current sample size, the <jats:italic>ABCB1<\/jats:italic> (rs1045642, C&amp;gt;T) CC + CT ratio in the observation subgroup tends to be higher than that in the control subgroup compared to TT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p><jats:italic>OPRM1<\/jats:italic> (rs1799971) AA genotype patients have a higher risk of ADR. <jats:italic>OPRM1<\/jats:italic> AA genotype patients should pay more attention to ADR, and the dosage can be initiated at low levels. The association between dose demand and SNPs still needs to be evaluated in larger cohorts. Meanwhile, particular attention should be given to the <jats:italic>ABCB1<\/jats:italic> gene.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1629866","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T08:44:48Z","timestamp":1754988288000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["A case\u2013control study on the individualized use of opioid analgesics based on single-nucleotide polymorphism"],"prefix":"10.3389","volume":"16","author":[{"given":"Jing","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Han","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang-Wei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"13422","DOI":"10.1111\/adb.13422","article-title":"Epigenetic and sex differences in opioid use disorder in chronic pain: a real-world study linked with OPRM1 DNA methylation","volume":"29","author":"Agullo","year":"2024","journal-title":"Addict. Biol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/sj.clpt.6100385","article-title":"Association of ABCB1\/MDR1 and OPRM1 gene polymorphisms with morphine pain relief","volume":"83","author":"Campa","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/tpj.2014.59","article-title":"Association of OPRM1 A118G variant with risk of morphine-induced respiratory depression following spine fusion in adolescents","volume":"15","author":"Chidambaran","year":"2015","journal-title":"Pharmacogenomics"},{"key":"B4","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1002\/cpt.2149","article-title":"Clinical pharmacogenetics implementation consortium guideline for CYP2D6, OPRM1, and COMT genotypes and select opioid therapy","volume":"110","author":"Crews","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/add.14180","article-title":"Extended-release injectable naltrexone for opioid use disorder: a systematic review","volume":"113","author":"Jarvis","year":"2018","journal-title":"Addict."},{"key":"B6","doi-asserted-by":"publisher","first-page":"172778","DOI":"10.1016\/j.pbb.2019.172778","article-title":"Assessing the contribution of opioid- and dopamine-related genetic polymorphisms to the abuse liability of oxycodone","volume":"186","author":"Jones","year":"2019","journal-title":"Pharmacol. Biochem. Behav."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.13699\/j.cnki.1001-6821.2023.08.030","article-title":"Wang haixue overview of causal relationship evaluation methods for adverse reactions in drug clinical trials and reflections on existing problems","volume":"39","author":"Liu","year":"2023","journal-title":"Chin. J. Clin. Pharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1097\/fpc.0b013e32832b89da","article-title":"Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers","volume":"19","author":"Lotsch","year":"2009","journal-title":"Pharmacogenet Genom"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1177\/0091270010388033","article-title":"CYP3A5*3 affects plasma disposition of noroxycodone and dose escalation in cancer patients receiving oxycodone","volume":"51","author":"Naito","year":"2013","journal-title":"J. Clin. Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/fcp.12976","article-title":"Impacts of genetic polymorphisms and cancer cachexia on naldemedine pharmacokinetics and bowel movements in patients receiving opioid analgesics","volume":"38","author":"Nakatsugawa","year":"2024","journal-title":"Fundam. Clin. Pharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1002\/jcph.1873","article-title":"Pharmacogenomics and morphine","volume":"61","author":"Ofoegbu","year":"2021","journal-title":"J. Clin. Pharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4045\/tidsskr.18.0561","article-title":"A girl of early school-age with no response to opioids during general anaesthesia","volume":"139","author":"Olsen","year":"2019","journal-title":"Tidsskr. Nor. Laegeforen"},{"key":"B13","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1097\/ACO.0000000000000633","article-title":"Genetics and genomics in postoperative pain and analgesia","volume":"31","author":"Palada","year":"2018","journal-title":"Curr. Opin. Anaesthesiol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"116897","DOI":"10.1016\/j.biopha.2024.116897","article-title":"ABCB1 genetic polymorphisms affect opioid requirement by altering function of the intestinal P-glycoprotein","volume":"176","author":"Qin","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"B15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jpainsymman.2023.09.017","article-title":"Comparison of the effects of OPRM1 A118G polymorphism using different opioids: a prospective study","volume":"67","author":"Takemura","year":"2024","journal-title":"J. Pain Symptom Manage"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.4103\/0366-6999.243934","article-title":"Impact of CYP3A4*1G polymorphism on fentanyl analgesia assessed by analgesia nociception index in Chinese patients undergoing hysteroscopy","volume":"131","author":"Yan","year":"2018","journal-title":"Chin. Med. J(Engl)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/BSR20181211","article-title":"Effects of OPRM1 and ABCB1 gene polymorphisms on the analgesic effect and dose of sufentanil after thoracoscopic-assisted radical resection of lung cancer","volume":"39","author":"Zhao","year":"2019","journal-title":"Biosci. Rep."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e1009593","DOI":"10.1371\/journal.pgen.1009593","article-title":"High-throughput framework for genetic analyses of adverse drug reactions using electronic health records","volume":"17","author":"Zheng","year":"2021","journal-title":"PLoS Genet."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1629866\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T08:44:49Z","timestamp":1754988289000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1629866\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":18,"alternative-id":["10.3389\/fphar.2025.1629866"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1629866","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]},"article-number":"1629866"}}